← Eichor
Study identifier: NCT03261934 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

Condition: Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation  ·  Sponsor: Beijing University of Chinese Medicine

PhaseN/A
Planned participants2000
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Chronic atrophic gastritis (CAG) is acknowledged as the precancerous stage of gastric cancer (GC). The present study aims to developed risk assessment and syndrome evolution models of CAG malignant transformation events combining TCM indicators with modern medicine indicators. The proposed study is a registry study based participant survey conducted in 4 hospitals in Beijing, China. After obtaining informed consent, a total of 2000 study patients diagnosed with CAG will be recruited. 10-year follow-ups are carried out on-site in hospitals and off-site by telephone to track malignant transformation events.

This description comes directly from the study's public registry record.

Talk to the study team

Yin Zhang, MD  ·  86-17710830835  ·  coolzhangyin@sina.com

Xia Ding, MD  ·  dingx@bucm.edu.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Dongzhimen HospitalBeijing, Beijing Municipality, ChinaRecruiting
Wangjing HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03261934